Introduction: Everolimus selectively inhibits mammalian target of rapamycin complex 1 (mTORC1) and exerts an antineoplastic effect. Metabolic disturbance has emerged as a common and unique side effect of everolimus.
Objectives: We used targeted metabolomic analysis to investigate the effects of everolimus on the intracellular glycometabolic pathway.
Methods: Mouse skeletal muscle cells (C2C12) were exposed to everolimus for 48 h, and changes in intracellular metabolites were determined by capillary electrophoresis time-of-flight mass spectrometry. mRNA abundance, protein expression and activity were measured for enzymes involved in glycometabolism and related pathways.
Results: Both extracellular and intracellular glucose levels increased with exposure to everolimus. Most intracellular glycometabolites were decreased by everolimus, including those involved in glycolysis and the pentose phosphate pathway, whereas no changes were observed in the tricarboxylic acid cycle. Everolimus suppressed mRNA expression of enzymes related to glycolysis, downstream of mTOR signaling enzymes and adenosine 5'-monophosphate protein kinases. The activity of key enzymes involved in glycolysis and the pentose phosphate pathway were decreased by everolimus. These results show that everolimus impairs glucose utilization in intracellular metabolism.
Conclusions: The present metabolomic analysis indicates that everolimus impairs glucose metabolism in muscle cells by lowering the activities of glycolysis and the pentose phosphate pathway.
Keywords: CE-TOFMS; Everolimus; Glycometabolism; Hyperglycemia; Metabolomics; mTOR inhibitor.
Conflict of interest statement
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
Research involving human participants and/or animals
This article does not contain any study using human or animals.
Increased metabolite levels of glycolysis and pentose phosphate pathway in rabbit atherosclerotic arteries and hypoxic macrophage.PLoS One. 2014 Jan 23;9(1):e86426. doi: 10.1371/journal.pone.0086426. eCollection 2014. PLoS One. 2014. PMID: 24466087 Free PMC article.
Fermentation of xylose causes inefficient metabolic state due to carbon/energy starvation and reduced glycolytic flux in recombinant industrial Saccharomyces cerevisiae.PLoS One. 2013 Jul 9;8(7):e69005. doi: 10.1371/journal.pone.0069005. Print 2013. PLoS One. 2013. PMID: 23874849 Free PMC article.
Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma.Oncotarget. 2015 May 30;6(15):13371-86. doi: 10.18632/oncotarget.3823. Oncotarget. 2015. PMID: 25945836 Free PMC article.
Metabolic phenotype of bladder cancer.Cancer Treat Rev. 2016 Apr;45:46-57. doi: 10.1016/j.ctrv.2016.03.005. Epub 2016 Mar 8. Cancer Treat Rev. 2016. PMID: 26975021 Review.
Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Semin Oncol. 2009. PMID: 19963098 Review.
Cited by 1 article
CE-MS for metabolomics: Developments and applications in the period 2016-2018.Electrophoresis. 2019 Jan;40(1):165-179. doi: 10.1002/elps.201800323. Epub 2018 Oct 1. Electrophoresis. 2019. PMID: 30232802 Free PMC article. Review.
- Barnes BR, Glund S, Long YC, Hjalm G, Andersson L, Zierath JR. 5′-AMP-activated protein kinase regulates skeletal muscle glycogen content and ergogenics. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2005;19(7):773–779. doi: 10.1096/fj.04-3221com. - DOI - PubMed
- Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824. doi: 10.1016/S0140-6736(12)61767-X. - DOI - PubMed